In a double-blind randomized placebo-controlled study, the effects of intravenous glutamate infusion on myocardial haemodynamics and metabolism were studied in 22 patients undergoing routine coronary artery bypass graft (CABG) surgery. Immediately after aortic cross-clamp release, an intravenous infusion of a solution of glutamate (125 mmol:l − 1 ) at a rate of 1.5 ml:h − 1 :kg − 1 was given over 1 h to 11 patients (G group). The other 11 patients received a placebo infusion (0.9 % NaCl) (P group). Haemodynamic functions and rates of exchange of glucose, non-esterified fatty acids and lactic acid over the heart were measured before sternotomy (T1), 40 min after cross-clamp release (T2) and 4 h after cross-clamp release (T3). At T2, decreases were seen in comparison with T1 in systemic vascular resistance index, and increases were seen in cardiac index and coronary sinus flow. All of these changes were greater in the G group than in the P group (P 0.05). Myocardial glutamate consumption increased 2-fold after glutamate administration. No significant changes were observed in the myocardial utilization of glucose, lactate or non-esterified fatty acids between the P and the G groups at T1, T2 or T3. These data show that an intravenous glutamate infusion after routine CABG surgery significantly improved cardiac haemodynamic performance without direct effects on cardiac substrate metabolism. This suggests that a reduction of the afterload via a peripheral vasodilatory effect is the main mechanism leading to the observed changes in haemodynamics. Earlier claims that patients with post-operative cardiac failure show metabolic benefits from the glutamate infusion do not seem to apply to patients undergoing routine CABG surgery.
The effect of glutamate infusion on cardiac performance is independent of changes in metabolism in patients undergoing routine coronary artery bypass surgery
A B S T R A C T
In a double-blind randomized placebo-controlled study, the effects of intravenous glutamate infusion on myocardial haemodynamics and metabolism were studied in 22 patients undergoing routine coronary artery bypass graft (CABG) surgery. Immediately after aortic cross-clamp release, an intravenous infusion of a solution of glutamate (125 mmol:l − 1 ) at a rate of 1.5 ml:h − 1 :kg − 1 was given over 1 h to 11 patients (G group). The other 11 patients received a placebo infusion (0.9 % NaCl) (P group). Haemodynamic functions and rates of exchange of glucose, non-esterified fatty acids and lactic acid over the heart were measured before sternotomy (T1), 40 min after cross-clamp release (T2) and 4 h after cross-clamp release (T3). At T2, decreases were seen in comparison with T1 in systemic vascular resistance index, and increases were seen in cardiac index and coronary sinus flow. All of these changes were greater in the G group than in the P group (P 0.05). Myocardial glutamate consumption increased 2-fold after glutamate administration. No significant changes were observed in the myocardial utilization of glucose, lactate or non-esterified fatty acids between the P and the G groups at T1, T2 or T3. These data show that an intravenous glutamate infusion after routine CABG surgery significantly improved cardiac haemodynamic performance without direct effects on cardiac substrate metabolism. This suggests that a reduction of the afterload via a peripheral vasodilatory effect is the main mechanism leading to the observed changes in haemodynamics. Earlier claims that patients with post-operative cardiac failure show metabolic benefits from the glutamate infusion do not seem to apply to patients undergoing routine CABG surgery.
INTRODUCTION
Previous studies have shown that there are abnormalities in cardiac substrate metabolism in patients with coronary artery disease (CAD) [1] [2] [3] [4] [5] . The most striking observation was a decrease in the use of blood lactate and of plasma non-esterified fatty acids (NEFA), substrates which are normally the main fuels in the healthy human heart [6] . The use of blood glucose was increased in most of the patients, and in some of the patients with severe CAD lactate was released instead of being consumed [1] [2] [3] . Similar abnormalities in cardiac substrate metabolism have also been observed early after coronary artery bypass graft (CABG) surgery [4] [5] [6] [7] . More metabolic abnormalities were seen by Pisarenko et al. [8] in patients with post-operative cardiac failure than in a recent study by our own group [4] in patients with less severe CAD after routine cardiac surgery using state-of-the-art surgical procedures and relatively brief cross-clamp times. Intravenous glutamate infusion in the first 1 h after cardiac surgery not only improved (normalized) substrate metabolism, but in parallel also improved cardiac index and left ventricular stroke index [8, 9] . Pisarenko and colleagues [3, 10, 11] assumed, but did not prove, that the changes in metabolism and performance after CABG surgery were mechanistically linked. They suggested that glutamate and aspartate facilitate the recovery of oxidative metabolism during reperfusion of the myocardium by activation of the malate-aspartate shuttle in the cytosol [3, [10] [11] [12] . This would accelerate the transfer of reducing equivalents to the respiratory chain in the mitochondria [10] .
In studies using perfused rat or rabbit hearts, ischaemia and hypoxia decreased the myocardial glutamate concentration and cardiac performance in parallel, while the addition of glutamate and tricarboxylic acid cycle intermediates to the perfusion or incubation medium stimulated ATP production and cardiac work [13] [14] [15] [16] . Mechanical recovery following global ischaemia in isolated rat and rabbit hearts was also more complete in the presence of glutamate [16, 17] . The CABG procedure also leads to a substantial fall in the myocardial glutamate concentration in humans [18] . In a pilot study using isotopically labelled ["&N]-and ["$C]glutamate [19] , we recently obtained evidence that the main fate of glutamate extracted by the human heart is a quantitative conversion into tricarboxylic acid cycle intermediates. Together these data seem to suggest that intravenous glutamate infusion potentially may improve cardiac performance following CABG surgery, via a more rapid recovery of the substrate flux through the tricarboxylic acid cycle and an increased contribution of the respiratory chain to cellular ATP production. After routine CABG we previously [4] observed only minor abnormalities in cardiac substrate metabolism in comparison with those seen in earlier studies using patients with evident postoperative cardiac failure [5, 6, 8] . The main aim of the present study was to investigate whether intravenous glutamate infusion would have a positive effect on cardiac performance and metabolism in patients after routine CABG surgery, as it is not clear whether these patients may also benefit from glutamate administration. Our hypothesis was that the effect on cardiac performance would be smaller in the latter group, when the effect would indeed be mechanistically linked to the observed abnormalities in substrate metabolism as suggested above. This study, in other words, also aims to provide information on the mechanism behind the effect of glutamate observed in previous studies using patients with severe abnormalities in both cardiac performance and metabolism [8, 20] . Therefore the effect of intravenous glutamate infusion was investigated in a doubleblind randomized placebo-controlled study using 22 patients undergoing routine CABG surgery, as described previously [4] .
METHODS
The study was approved by the medical ethics committee, and written informed consent was obtained from each subject. A total of 22 patients scheduled for CABG surgery, with two-or three-vessel disease, were included in the study. Patients included had angina pectoris with a New York Heart Association (NYHA) III\IV classification, a left ventricular ejection fraction of 50 % and no evidence of valvular heart disease. Patients with diabetes mellitus, other metabolic diseases, renal or liver insufficiency, malignant hypertension or neurological disorders were excluded. Randomization of the patients was carried out by the Pharmacy Department. A blind envelope was drawn and the intravenous solution was prepared ; thus, during administration of glutamate or placebo, the clinicians did not know which solution was given.
Anti-anginal therapy was continued until surgery. At 30 min after oral premedication with 60 µg:kg −" lorazepam, the patients were transported to the operating theatre. After insertion of a peripheral intravenous cannula and a radial arterial line, anaesthesia was induced with midazolam (60-80 µg:kg −" ), sufentanil (1-1.5 µg:kg −" bolus), etomidate (0.2-0.3 mg:kg −" ) and pancuronium bromide (0.1 mg:kg −" ) [21] . Anaesthesia was maintained with sufentanil at 5 µg:kg −" :h −" before extracorporeal circulation (ECC), 2.5 µg:kg −" :h −" during ECC and 1.25 µg:kg −" :h −" after ECC. Nitroglycerin at 0.5 µg:kg −" :min −" was started after induction of anaesthesia [22] . In the ICU (Intensive Care Unit), 2-3 mg:kg −" :h −" propofol was given for sedation (Ramsay scale 4). Analgesia was provided with an infusion of alfentanyl at 14-20 µg:kg −" :h −" over 4 h post-operatively. Mechanical ventilation was performed with an oxygen\air mixture with a fractional inspired O # concentration of 50 %, a tidal volume of 10-12 ml:kg −" to an end-tidal partial pressure of CO # of 4 %. A pulmonary artery catheter (Baxter, Irvine, CA, U.S.A.) and a coronary sinus (CS) catheter (Elecath ; ElectroCatheter Corp., Rahway, NJ, U.S.A.) were inserted via two 7 french Arrow2 introducers into the right internal jugular vein. The pulmonary artery catheter was floated into position guided by measured pressures, and the position of the distal tip was verified by fluoroscopy. Correct placement of the CS catheter was controlled by fluoroscopy, continuous pressure monitoring at the distal tip, oxygen saturation and CS flow measurements. CS flow measurements were performed by thermodilution with a continuous infusion of saline (0.9 % NaCl) at room temperature during a period of 30 s at a flow rate of 50 ml:min −" (Metrad2 Mark V infusion pump) through the distal lumen of the CS catheter.
Correct placement of the CS catheter was verified regularly by blood-gas samples, flow measurements and peroperatively by palpation of the catheter by the cardiac surgeon. In the ICU the position was verified by a chest X-ray with 5 ml of contrast medium in the CS catheter. Immediately after aortic cross-clamp release, an intravenous solution was given for 1 h at a rate of 1.5 ml: kg −" :h −" . This solution contained either 0.9 % NaCl (placebo ; P group) or 125 mmol:l −" glutamate (G group) at a flow rate of 1.5 ml:kg −" :h −" (0.1875 mmol:kg −" :h −" glutamate). The exact composition of this solution was 18.4 g of L-glutamic acid and 1.6 g of NaCl, adjusted to a pH of 6 with NaOH. The osmolarity of the solution was 280 mosmol:kg −" . CS flow, haemodynamic measurements, and arterial and CS blood samples were obtained before ECC (T1), 40 min after aortic cross-clamp release (T2) and 4 h after aortic cross-clamp release (T3).
Blood samples were centrifuged immediately at 1500 g for 5 min at 4 mC, and the plasma was frozen in liquid nitrogen and stored at k80 mC until analysis. Samples for NEFA and glycerol analysis were collected in EDTA tubes, and other samples were collected in sodium heparin tubes. Lactate was determined enzymically on a COBAS-MIRA instrument using lactate dehydrogenase (Boehringer no. 127876 ; Boehringer, Mannheim, Germany). Before being frozen, samples for measurement of lactate and glucose were deproteinized by adding 25 µl of a solution of trichloroacetic acid (5 g\10 ml) to 250 µl of plasma.
Blood oxygen saturation was measured directly with an OSM3 Hemoximeter2 (Radiometer, Copenhagen, Denmark). Blood pH and partial pressures of CO # and O
#
were measured with an ABL-505 (Radiometer). Arterial and CS blood O # concentrations were calculated from these variables. Myocardial oxygen consumption, myocardial oxygen extraction and myocardial oxygen delivery were calculated. Heart rate, mean arterial pressure, central venous pressure, pulmonary capillary wedge pressure, mean pulmonary artery pressure, cardiac output and CS flow were measured. Systemic vascular resistance index (SVRI), CS resistance, cardiac index, stroke volume index and left ventricular stroke work index were calculated. ECC was performed at a flow of 2.4 litres:m −# body surface area, while maintaining a mean blood pressure of between 60 and 80 mmHg. Patients were cooled to a blood temperature of 28-30 mC. Immediately after aortic cross-clamping, St. Thomas's cardioplegic solution was given into the aortic root until electrical silence was observed ; thereafter another 250 ml of solution was perfused. After completion of CABG and re-warming to a maximal nasopharyngeal temperature of 36.5 mC and a rectal temperature of at least 34 mC, patients were weaned from the ECC.
For statistical analysis, the Wilcoxon Mann-Whitney test was applied to test the significance of within-patient changes from T1 to T2 and from T1 to T3. Differences were considered significant at P 0.05.
RESULTS
Patients included in the P group (n l 11) and the G group (n l 11) were comparable with regard to age, number of grafts, duration of ECC, aortic cross-clamp time and NYHA classification ( Table 1 ). The postoperative course in all patients was uneventful. Glutamate administration (125 mmol:l −" ) was started directly after aortic cross-clamp release, and was continued for 1 h at a rate of 1.5 ml:kg −" :h −" .
Effects of glutamate administration on haemodynamic parameters
Heart rate in the G group increased from 59p2 beats:min −" at T1 to 76p3 beats:min −" at T2 (P 0.05) ( Table 2 ). The cardiac index increased after glutamate administration from 2.39p0.1 litres: min −" :m −# at T1 to 3.30p0.20 litres:min −" :m −# at T2 (P 0.05) ( Table 2 ). The percentage increase in cardiac index when compared with the value at T1 (taken as 100 %) was significantly higher in the G group than in the P group at both T2 (P 0.005) and at T3 (P 0.05) (Figure 1) . SVRI in the G group decreased from 2351p151 dyn:s −" :cm −& :m −# at T1 to 1523p115 dyn: Table 2 ). The percentage decrease in SVRI from T1 to T2 in the G group was significantly larger than that in the P group (P 0.05) (Figure 1 ). CS flow increased from 109p16 ml:min −" at T1 to 154p17 ml:min −" at T2 in the G group (P 0.05) ( Table 2 ). The percentage increases in CS flow at T2 and T3 compared with the value at T1 (taken as 100 %) were significantly greater in the G group than in the P group (Figure 1 ). CS resistance (Table 2) tended to be lower in the G group than in the P group at T2, and was significantly lower at T3.
Effects of glutamate administration on myocardial oxygen parameters
Myocardial oxygen delivery in the G group increased from 8. There were no significant differences in myocardial oxygen delivery, myocardial oxygen consumption or myocardial oxygen extraction between the G and P groups at any time points.
Effects of glutamate administration on cardiac substrate metabolism
During administration of glutamate, no significant changes could be observed in the arterial glucose con-Effect of glutamate infusion on cardiac metabolism
Figure 1 Haemodynamic changes in cardiac index (A), SVRI (B) and CS flow (C) in CABG patients
Significance of differences : *P 0.05, FP 0.005 (placebo compared with glutamate). centration or the arteriovenous glucose difference (Table  3) . Myocardial glucose delivery in the G group increased from 0.83p0.11 mmol:min −" at T1 to 1.19p0.13 mmol: min −" at T2 (P 0.05). No significant changes could be observed in glucose consumption or myocardial glucose extraction during glutamate administration. There were no significant differences in glucose consumption at any time point between the G and P groups.
The arterial NEFA concentration in the G group decreased from 247p54 µmol:l −" at T1 to 158p 30 µmol:l −" at T2 (P 0.05) ( Table 3) . Similar changes were seen in the P group. The arteriovenous NEFA concentration difference also increased in the G group, from 25p8 µmol:l −" at T2 to 74p10 µmol:l −" at T3 (P 0.05). Myocardial NEFA consumption decreased from 7.1p2.2 µmol:min −" at T1 to 3.5p1.1 µmol:min −" at T2 (P 0.05), and subsequently increased to 10.2p2.0 µmol:min −" at T3 (P 0.05) ( Table 3 ). There were no significant differences in NEFA consumption at any time point between the G and P groups.
The arterial lactate concentration did not change between T1 and T3 in either of the groups. The arteriovenous lactate concentration difference decreased in the G group only, from 0.50p0.06 mmol:l −" at T1 to 0.23p0.04 mmol:l −" at T2 (P 0.005), due, at least in part, to the increases in CS blood flow. Myocardial lactate consumption in the G group decreased from 50p10 µmol:min −" at T1 to 36p9 µmol:min −" at T2 (P 0.05). Myocardial lactate extraction in the G group decreased from 43p6 % at T1 to 17p3 % at T2 (P 0.05), and increased thereafter to 22p6 % at T3 (P 0.05) ( Table 3) . Myocardial lactate extraction also decreased in the P group, from 25p9 % at T1 to 14p5% at T2 (P 0.05). There were no significant differences in lactate consumption between the G and the P groups at any time point.
Effects of glutamate administration on glutamate concentrations and consumption
During glutamate administration, the arterial glutamate concentration increased from 57p5 µmol:l −" at T1 (before glutamate administration) to 234p28 µmol:l −" at T2 (P 0.005) ( Table 4 ). Myocardial glutamate delivery also increased, from 5.1p1 µmol:min −" at T1 to 30.3p4.4 µmol:min −" at T2 (Table 4) . Myocardial glutamate consumption at T2 was higher in the G group (7.6p1.6 µmol:min −" ) than in the P group (2.7p0.8 µmol:min −" ).
DISCUSSION
The most important observations in the present study were that, during intravenous glutamate infusion after CABG surgery, the cardiac index and CS blood flow increased, and SVRI and CS resistance decreased, compared with those in subjects receiving placebo. These changes in cardiac performance are similar to those reported previously by Pisarenko et al. [8] in patients with postoperative cardiac failure after CABG surgery. The changes, furthermore, occurred after routine CABG surgery in our patients without significant effects on cardiac substrate metabolism. This suggests that the effect of glutamate on cardiac performance is not mediated primarily via an improvement in aerobic substrate metabolism, in contrast with suggestions made previously on the basis of effects observed in CABG patients with more severely compromised cardiac function [8] . During glutamate infusion the arterial glutamate concentration increased 5-fold and the myocardial glutamate uptake increased 2-fold compared with the P group. Similar quantitative results were obtained in earlier studies [8, 20] . Therefore the relationship between arterial glutamate concentration and myocardial glutamate uptake is not linear.
In our study, glutamate infusion did not lead to an increase in myocardial lactate consumption. This is in contrast with previous observations made by Svedjeholm et al. [23] and Pisarenko et al. [8] . The differences between the patients in [23] and [8] and those in our present study were that our patients had less severe CAD before surgery, did not show signs of post-operative cardiac failure, and had a higher rate of lactate uptake in the group receiving placebo. Some of the patients in the study of Pisarenko et al. [8] in fact showed release of lactate before the glutamate infusion was started, which turned into lactate uptake during glutamate infusion. This was the reason to suggest that the improvement in cardiac performance seen during glutamate infusion was linked mechanistically to an increased capacity of the mitochondria for aerobic ATP production. However, in the present study we did not observe significant changes in cardiac glucose, lactate or NEFA utilization between the G and P groups, suggesting that changes in substrate metabolism did not play a role in the alterations seen in cardiac haemodynamic performance. However, the small sample size might have led to small differences in cardiac substrate metabolism being missed. As a result of increased CS flow, and thus increased flow through the coronary arteries, the delivery of oxygen and blood-borne substrates was higher in the G group than in the P group. The consumption of substrates and oxygen nevertheless did not differ substantially between the two groups, suggesting that there was no limitation in oxygen and fuel supply in the P group. Only minor changes, e.g. impaired NEFA consumption and increased glucose consumption, were observed in the first 1 h after routine CABG surgery [4] . These changes were minimal in comparison with those seen previously by Effect of glutamate infusion on cardiac metabolism others [8, 23] in patients with post-operative cardiac failure. CS resistance and SVRI decreased more in the G group than in the P group (Table 3 ). These observations suggest that glutamate infusion immediately after CABG causes vasodilatation in both the systemic and coronary circulations. In our patients it is quite likely that the cardiac index in the G group (Table 3) increased as a consequence of this decrease in SVRI. The haemodynamic effects of glutamate infusion in the period after CABG surgery have been observed previously by others [8, 23] , and have even led to suggestions that glutamate infusion should form part of the treatment of severe cardiac failure after CABG surgery [3] .
It is notable that this effect of glutamate is limited to the post-CABG surgery period, as glutamate infusion did not influence resting cardiac haemodynamics in patients with stable CAD [24] . During pacing, glutamate infusion improved cardiac metabolism and had antiischaemic effects in patients with stable angina pectoris [2, 24] .
The main difference between the present study and previous ones [8, 23] is that we selected patients with minor CAD only. It is possible that impairments in oxygen and fuel supply or oxidation immediately after CABG [8, 23] play a causal role in the development of post-operative cardiac failure. Glutamate may, therefore, have a dual beneficial effect in patients with postoperative cardiac failure, as it may improve aerobic substrate metabolism and ATP production via a direct metabolic effect on the heart, and it may simultaneously improve the blood supply of oxygen and fuels to the periphery and the heart. Future research in patients with post-operative failure will be needed to establish the relative contributions of and the potential relationship between the two mechanisms.
In conclusion, the most important observation in the present study is that an intravenous glutamate infusion after routine CABG surgery significantly improved cardiac haemodynamic performance without direct effects on cardiac substrate metabolism. This suggests that a decrease in the afterload due to a peripheral vasodilatory effect is the main mechanism leading to the observed changes in haemodynamics. Patients undergoing routine CABG surgery did not show a metabolic or haemodynamic benefit from the glutamate infusion. These findings do not support the routine use of glutamate infusions following CABG surgery in patients with CAD with well preserved ventricular function.
